证券代码：300573 证券简称：兴齐眼药 公告编号：2025-042 沈阳兴齐眼药股份有限公司 2、现场会议时间：2025年9月15日（星期一）下午14:30。 3、网络投票时间：2025年9月15日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为2025年9月15日9:15—9:25，9:30—11:30和13:00— 15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为2025年9月15 日9:15至15:00期间的任意时间。 4、现场会议召开地点：沈阳市浑南区泗水街68号，沈阳兴齐眼药股份有限 公司E1号楼，二楼多功能厅。 5、会议召集人：公司董事会。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开方式：本次会议以现场投票与网络投票相结合的方式召开。 2025 年第二次临时股东大会决议公告 6、会议主持人：公司董事长刘继东先生。 7、股东出席情况： 出席本次股东大会现场会议和网络投票的股 ...

Group 1 - The "Quality Month" event in Liaoning Province was launched on September 10, 2025, focusing on brand building and high-quality development with the theme "Brand Power, Quality Wins the Future" [1] - The event served as a platform for discussing new paths for quality and brand work in the province, gathering various stakeholders [1] Group 2 - Several companies were recognized as "Liaoning Excellent Products," including Benxi Longshan Spring Beer Co., Ltd. and Huludao Yifeng (Group) Sportswear Co., Ltd. [3] - Other companies nominated for the "Liaoning Excellent Products" title included Shenyang Xingqi Eye Medicine Co., Ltd., Dayang Group, Liaoning Sangou Liquor Co., Ltd., and Liaoning Lingxiushan Shenghui Industrial Group Co., Ltd. [3] Group 3 - Shenyang Xingqi Eye Medicine Co., Ltd. shared the story of developing China's first cyclosporine eye drops for dry eye treatment after 18 years of research [5] - Dayang Group recounted its journey from employing 85 rural women to aiming to create the best suits in China and the world [5] - Benxi Longshan Spring Beer Co., Ltd. highlighted its commitment to quality and technological innovation in a competitive market [5] Group 4 - Liaoning Sangou Liquor Co., Ltd. emphasized its core value of "openness" through multiple reforms, enhancing its brand's historical significance [7] - Liaoning Lingxiushan Shenghui Industrial Group Co., Ltd. shared its health-oriented product development strategy to differentiate itself from industry giants [7] - Huludao Yifeng (Group) Sportswear Co., Ltd. narrated its evolution from a small vendor to a complete industry chain through technological innovation [7]

Core Insights - The event "Quality Month" in Liaoning Province was launched on September 10, 2025, focusing on brand building and high-quality development under the theme "Brand Synergy, Quality Wins the Future" [1] - The conference released the 2025 brand value evaluation results and the "Liaoning Province Quality Status White Paper (2024)", showcasing the improvement in brand competitiveness across key industries and enterprises in the province [1] - Representatives from 15 enterprises shared their brand growth stories, highlighting the innovative spirit and responsibility of Liaoning brands [1] Summary by Categories Brand Development - The event emphasized the importance of brand building in achieving high-quality development in Liaoning Province [1] - The theme of the conference, "Brand Synergy, Quality Wins the Future," reflects a strategic focus on enhancing brand value [1] Quality Assessment - The release of the 2025 brand value evaluation results provides a clear view of the competitive landscape among key industries and enterprises in Liaoning [1] - The "Liaoning Province Quality Status White Paper (2024)" summarizes the progress made in quality infrastructure and regulatory services over the past year [1] Case Studies - Companies such as Shenyang Xingqi Eye Pharmaceutical Co., Danyang Group, Anshan Falan Co., and Geerlao New Materials Co. presented their brand development experiences [1] - These case studies serve to illustrate the innovative approaches and commitments of Liaoning enterprises towards brand enhancement [1]

Group 1 - The company has multiple production lines that are GMP certified for the production of 0.01% atropine sulfate eye drops, which can meet current market demand [2] - The company will closely monitor changes in market demand and make timely arrangements for production capacity [2]

Core Viewpoint - The company is upgrading its "Quality Month" initiative to "Quality Season" to enhance quality management and cultural promotion, reflecting a commitment to quality standards and employee engagement [1][2][4]. Group 1: Quality Season Activities - The "Quality Season" will span two to three months starting in September, focusing on various dimensions such as quality culture, capability enhancement, innovation practices, and results promotion [3][4]. - Activities planned include management lectures, logo design competitions, quality management model presentations, quality knowledge lectures, skill competitions, and evaluations of outstanding quality personnel [3][4]. Group 2: Employee Engagement and Participation - The number of participants in quality activities has increased significantly, with over 2,600 employees involved in the 2024 "Quality Month," marking a new high [2]. - The company aims for deeper engagement, with participants taking on active roles in quality management rather than being mere observers [4]. Group 3: Strategic Importance - The initiative reflects the company's high-level commitment to quality work and culture, adhering to the principle that "first-class standards create first-class quality" [4]. - The transition to "Quality Season" is seen as a new starting point for deepening quality efforts within the company [4].

Group 1 - A total of 43 companies were investigated by institutions on September 1, with 26 companies being surveyed by funds, indicating a strong interest from institutional investors [1] - The most popular company among funds was Kaiying Network, which attracted 34 funds for investigation, followed by Xingqi Eye Medicine with 24 funds [1][2] - The surveyed companies spanned 17 industries, with the highest representation in the electric equipment, electronics, and pharmaceutical biology sectors, each having three stocks [1] Group 2 - Among the surveyed companies, only one had a total market value exceeding 50 billion yuan, while 17 companies had a market value below 10 billion yuan, including Sanfu Outdoor and Shouhua Gas [1] - In terms of market performance, 10 stocks among the surveyed companies increased in value over the past five days, with the highest gains seen in Kunheng Shunwei (15.13%), Xingqi Eye Medicine (14.77%), and Huali Chuantong (14.39%) [1][2] - Conversely, 16 stocks experienced declines, with Guangxin Technology, Xiangsheng Medical, and Zhucheng Technology showing the largest drops of 8.37%, 7.83%, and 7.57% respectively [1][2]

Summary of the Conference Call for Xingqi Eye Pharmaceutical Company Overview - **Company**: Xingqi Eye Pharmaceutical - **Industry**: Ophthalmic Pharmaceuticals Key Financial Performance - **Revenue**: 11.62 billion CNY in H1 2025, a year-on-year increase of 30.38% [2][3] - **Net Profit**: 3.35 billion CNY, a year-on-year increase of 97.75% [2][3] - **Dividend Proposal**: Cash dividend of 7 CNY per 10 shares, subject to shareholder approval [2][3] Research and Development Progress - **R&D Investment**: 1.0 billion CNY, an increase of 8.11%, representing 8.64% of revenue [2][4] - **Product Approvals**: - Heafluprost eye drops approved - Lidocaine eye gel in Phase III clinical trials - SQ22,031 eye drops in Phase II clinical trials for neurotrophic keratitis, listed as a rare disease drug [2][4][5] - **Innovative Products**: - 60 approved ophthalmic drugs, with 38 in the medical insurance directory and 6 in the national essential drug list [4] - SQ22,031 eye drops and SQ129 vitreous sustained-release injection under development [9] Market Strategy and Sales Performance - **Atropine Sales**: - Widely distributed in public hospitals and major private groups, covering nearly 17,000 retail pharmacies and online platforms [2][10] - Sales growth driven by a comprehensive marketing strategy and collaboration in myopia prevention [12] - **Sales Team**: Over 500 professional promotion specialists, with plans for further expansion based on market conditions [10][12] - **Market Coverage**: - Multi-channel marketing strategy including both online and offline channels [12][18] - Focus on enhancing brand influence and customer satisfaction [7][8] Future Outlook and Market Trends - **Market Potential**: - Significant growth potential in the myopia prevention market, with over 100 million schoolchildren affected [24] - Anticipated stable gross margin due to increased sales scale and operational efficiency [21] - **Product Pipeline**: - Continued focus on innovative drug development in ophthalmology, including treatments for myopia, dry eye, and other eye diseases [23][25] - Plans to expand into international markets with existing and new products [22] Additional Insights - **Quality Management**: - Achieved national-level green factory certification and implemented stringent quality control measures [6] - **Patient Compliance**: - High compliance rates among pediatric patients using atropine, with ongoing efforts to improve disease education and treatment adherence [18][19] - **Clinical Guidelines**: - Received endorsements from multiple clinical guidelines, enhancing the credibility of products like cyclosporine eye drops [20] This summary encapsulates the key points from the conference call, highlighting the financial performance, R&D advancements, market strategies, and future outlook for Xingqi Eye Pharmaceutical.

Group 1: Aohua Endoscopy - The company anticipates a decline in overall gross margin due to an increase in overseas revenue share and changes in product structure by the first half of 2025 [1] - Sales, R&D, and management expenses have decreased year-on-year, primarily due to the reversal of share-based payment expenses [1] - The overseas business has shown growth due to progress in multi-country access and marketing layout, enhancing global brand influence [1] - The domestic market strategy focuses on both tertiary hospitals and county-level markets, with multiple academic events and grassroots training conducted [1] - Demand for flexible endoscopes is driven by the popularization of early cancer screening, leading to sustained growth in new equipment, replacements, and endoscope body replacements [1] - The company is expanding its product lines beyond gastroenterology to include respiratory, urology, ENT, and hepatobiliary surgery [1] Group 2: Xingqi Eye Medicine - The company is developing an innovative drug, SQ-22031 eye drops, which is a Class 1 biopharmaceutical for treating neurotrophic keratitis and dry eye syndrome [2] - The Phase I clinical trial for this product has successfully obtained a clinical research report [2] Group 3: Mylande - The company achieved revenue of 241 million yuan, a year-on-year increase of 5.62%, while net profit attributable to shareholders was 63.92 million yuan, a decrease of 11.96%, mainly due to the disposal of non-performing assets [3] - Revenue from reproductive rehabilitation and anti-aging business reached 79.84 million yuan, a year-on-year increase of 42.45% [3] - The decline in gross margin is attributed to adjustments in new product promotion strategies and an increase in orders from major clients [3] - The company is focusing on non-invasive brain-machine interfaces and has accumulated technology in multi-modal physiological signal acquisition [3] - Emotional interaction products have reached the prototype stage, with plans to conduct clinical pre-experiments within the year [3] - Multi-center clinical research is aiding product entry into hospitals, and the overseas business is primarily targeting the Southeast Asian market [3] - The company aims to establish a model in Jiangsu and Zhejiang provinces for its health management center this year [3] - The company adheres to a dual-driven strategy of "one end more serious, one end more consumer" [3] Group 4: Company Overview - Shanghai Chengrui Investment Management Co., Ltd. was established in May 2010 with a registered capital of 110 million yuan [4] - The company became a private equity fund manager in April 2014 and has been recognized for its stable development and diverse client base, including banks, private banks, securities firms, insurance companies, trusts, and various institutional investors [4] - The investment research team consists of 33 highly qualified professionals with strong educational backgrounds and extensive investment experience [4] - The company has received numerous awards and recognitions, including being listed among the top private equity firms in China and winning various industry awards [4]

Group 1: Company Highlights - Changchun High New has made breakthrough progress in using AI large models to design highly alkaline single-domain antibodies, successfully completing the development of a protein product that has entered 5000-liter scale production [1] - Zhongchuang Zhiling's subsidiary Zhengmeiji Shuyun Intelligent Technology has invested heavily in building a robotic welding laboratory, promoting the transition of welding technology from manual to intelligent [2] - BoRui Pharmaceutical has submitted IND applications for BGM0504 and BGM1812 for weight loss indications in both the US and China, with BGM0504 entering Phase I clinical trials approved by the FDA [3] - Xingqi Eye Medicine's SQ-22031 eye drops, an innovative drug for treating neurotrophic keratitis and dry eye syndrome, have completed Phase I clinical trials [4] - Sunshine Nuohe reported a revenue of 7.3371 million yuan from equity-sharing projects, a year-on-year increase of 119.73%, with clinical business revenue reaching 279 million yuan, a 29% increase year-on-year [5] Group 2: Investment Management Overview - Shanghai Danyi Investment Management Partnership, established in April 2015, has a paid-in capital of 10 million yuan and is registered with the Asset Management Association of China [5] - The core executives of the company have over ten years of investment research experience, having previously worked as investment managers or chief researchers at prominent institutions [5]

Core Viewpoint - The A-share ophthalmology medical concept stocks experienced a collective surge, with several companies reaching their daily limit up, indicating strong market interest and potential growth in the sector [1][2]. Group 1: Stock Performance - Companies such as Shapais, Innovation Medical, and Xingqi Eye Medicine saw significant stock price increases, with Xingqi Eye Medicine rising over 14% and Shapais reaching a limit up [1][2]. - The ophthalmology sector index rose by 2.17%, reflecting overall positive sentiment in the market [2]. Group 2: Market News - Recent rumors indicated that the Henan Provincial Eye Hospital would stop supplying its self-made 0.01% atropine sulfate eye drops due to the expiration of its registration, which has led to increased attention on the market for similar products [3][4]. - The hospital confirmed that the 0.01% atropine sulfate eye drops had ceased production since December of the previous year, with current sales being from existing inventory [3]. Group 3: Product and Market Dynamics - Atropine sulfate eye drops have gained recognition as a "myopia miracle drug," particularly for children aged 6 to 12, and are recommended in various authoritative guidelines for myopia management [4]. - Xingqi Eye Medicine's atropine sulfate eye drops received approval for market entry in March 2024, leading to a significant increase in its stock price and revenue growth [4]. - In 2024, Xingqi Eye Medicine reported a revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, up 40.84% [4]. Group 4: Competitive Landscape - The market for atropine sulfate eye drops is becoming increasingly competitive, with several companies, including Zhaoke Ophthalmology and Hengrui Medicine, advancing their own products [5]. - Shapais is also in the process of developing its own version of atropine sulfate eye drops, which is currently in Phase III clinical trials [5]. - Xingqi Eye Medicine is expected to continue its upward trajectory with ongoing product iterations and new submissions for market approval [5].